Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2004 1
2005 3
2006 6
2007 2
2008 5
2009 3
2010 2
2011 5
2012 6
2013 8
2014 10
2015 8
2016 2
2017 5
2018 7
2019 2
2020 7
2021 7
2022 9
2023 8
2024 6
2025 6
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ayen c (129 results)?
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies.
Trickey A, McGinnis K, Gill MJ, Abgrall S, Berenguer J, Wyen C, Hessamfar M, Reiss P, Kusejko K, Silverberg MJ, Imaz A, Teira R, d'Arminio Monforte A, Zangerle R, Guest JL, Papastamopoulos V, Crane H, Sterling TR, Grabar S, Ingle SM, Sterne JAC. Trickey A, et al. Among authors: wyen c. Lancet HIV. 2024 Mar;11(3):e176-e185. doi: 10.1016/S2352-3018(23)00272-2. Epub 2024 Jan 24. Lancet HIV. 2024. PMID: 38280393 Free PMC article.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY. Osiyemi O, et al. Among authors: wyen c. Clin Infect Dis. 2022 Sep 29;75(6):975-986. doi: 10.1093/cid/ciac036. Clin Infect Dis. 2022. PMID: 35079789 Free PMC article. Clinical Trial.
Dynamics and durability of HIV-1 neutralization are determined by viral replication.
Schommers P, Kim DS, Schlotz M, Kreer C, Eggeling R, Hake A, Stecher M, Park J, Radford CE, Dingens AS, Ercanoglu MS, Gruell H, Odidika S, Dahlhaus M, Gieselmann L, Ahmadov E, Lawong RY, Heger E, Knops E, Wyen C, Kümmerle T, Römer K, Scholten S, Wolf T, Stephan C, Suárez I, Raju N, Adhikari A, Esser S, Streeck H, Duerr R, Nanfack AJ, Zolla-Pazner S, Geldmacher C, Geisenberger O, Kroidl A, William W, Maganga L, Ntinginya NE, Georgiev IS, Vehreschild JJ, Hoelscher M, Fätkenheuer G, Lavinder JJ, Bloom JD, Seaman MS, Lehmann C, Pfeifer N, Georgiou G, Klein F. Schommers P, et al. Among authors: wyen c. Nat Med. 2023 Nov;29(11):2763-2774. doi: 10.1038/s41591-023-02582-3. Epub 2023 Nov 13. Nat Med. 2023. PMID: 37957379 Free PMC article.
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Meissner EG, Ramgopal M, Ruane PJ, Sanchez W, Crofoot G, Routy JP, Brinson C, DeJesus E, Martorell CT, Tellez M, Yokomaku Y, O'Reilly M, Lupo S, Schellberg S, Lezama-Mora JI, Chin B, Aizen K, D'Antoni ML, Huang H, Mponponsuo K, Montezuma-Rusca JM, Sklar P, Rhee M, Hung CC; ARTISTRY-2 Study Group. Meissner EG, et al. Lancet HIV. 2026 Aug;13(8):e538-e547. doi: 10.1016/S2352-3018(26)00078-0. Epub 2026 May 6. Lancet HIV. 2026. PMID: 42105781 Clinical Trial.
Malignant lymphoma in the HIV-positive patient.
Meister A, Hentrich M, Wyen C, Hübel K. Meister A, et al. Among authors: wyen c. Eur J Haematol. 2018 Jul;101(1):119-126. doi: 10.1111/ejh.13082. Epub 2018 May 22. Eur J Haematol. 2018. PMID: 29663523 Review.
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, Krist L, Lemhöfer C, Lieb W, Lorenz-Depiereux B, Mikolajczyk R, Montellano FA, Reese JP, Schreiber S, Skoetz N, Störk S, Vehreschild JJ, Witzenrath M, Grill E; NAPKON Study Group. Shi Y, et al. Infection. 2023 Dec;51(6):1679-1694. doi: 10.1007/s15010-023-02043-6. Epub 2023 May 25. Infection. 2023. PMID: 37231313 Free PMC article.
Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study.
Hillus D, Le NH, Tober-Lau P, Fietz AK, Hoffmann C, Stegherr R, Huang L, Baumgarten A, Voit F, Bickel M, Goldstein G, Wyen C, Stocker H, Wünsche T, Lee M, Schulbin H, Vallée M, Bohr U, Potthoff A, Cordes C, Isner C, Knox B, Carmona A, Stobäus N, Balicer R; SEMVAc Study Group; Kurth F, Sander LE. Hillus D, et al. Among authors: wyen c. Lancet Infect Dis. 2025 Jul;25(7):775-787. doi: 10.1016/S1473-3099(25)00018-0. Epub 2025 Mar 18. Lancet Infect Dis. 2025. PMID: 40118087 Free article.
Use of Preventive Measures for Cardiovascular Disease in People With HIV.
Jaschinski N, Neesgaard B, Wit F, Van der Valk M, Kowalska J, Ridolfo AL, Günthard HF, Stöckle M, Wallner E, Nowak P, Castagna A, d'Arminio Monforte A, Petoumenos K, Hoy JF, Hosein S, Lundgren J, Garges H, Rogatto F, Young L, Peters L, Mocroft A, Ryom L; RESPOND Study Group. Jaschinski N, et al. Open Forum Infect Dis. 2025 Sep 24;12(10):ofaf586. doi: 10.1093/ofid/ofaf586. eCollection 2025 Oct. Open Forum Infect Dis. 2025. PMID: 41169531 Free PMC article.
Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.
Berenguer J, Ryan P, Lutz T, Martín-Carbonero L, Pérez-Latorre L, Vivancos MJ, Navarro J, Navarro-Soler R, Ferrero OL, Palacios R, Wyen C, Domingo P, Monin MB, Camino X, Montero M, Killer A, Malin JJ, de Los Santos I, Esser S, Morano LE, López-Cruz I, Valencia J, Vogelmann R, Mauss S, Rivero A, Elamouri F, Hidalgo-Tenorio C, Cielniak I, van Bremen K, Pérez-Somarriba J, Sanz J, Rozpłochowski B, Beer D, Baumgarten A, Haberl A, Galindo MJ, Fariñas MC, Raczynska A, Voit F, Qurishi N, Noe S, Reus S, Khaykin P, Schneeweiss SM, Wandeler G, Boyd A, de Miguel M, Bellón JM, Parczewski M, Rockstroh JK. Berenguer J, et al. Among authors: wyen c. Clin Infect Dis. 2026 Jun 1:ciag341. doi: 10.1093/cid/ciag341. Online ahead of print. Clin Infect Dis. 2026. PMID: 42219602
115 results